Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

During the 2023 Florida Society of Clinical Oncology Fall Session, several Florida Cancer Specialists & Research Institute, LLC, physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that hematologist and medical oncologist Andrea Katz, MD has joined the statewide practice.

A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.

Florida Cancer Specialists & Research Institute, LLC has appointed medical oncologist and hematologist Richard McDonough, MD as Director of Patient Advocacy for the statewide practice.

Florida Cancer Specialists & Research Institute, LLC is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma.

Innovative new technologies being used exclusively by Florida Cancer Specialists & Research Institute, LLC in Ocala and The Villages are helping to target tumors more precisely, reduce side effects and enhance comfort for patients receiving radiation therapy for the treatment of certain cancers, including breast cancer and head and neck cancers.

Research conducted by Florida Cancer Specialists & Research Institute, LLC recently confirmed the effectiveness of a new medication in protecting bone marrow of patients who receive chemotherapy for extensive-stage small cell lung cancer.

Florida Cancer Specialists & Research Institute physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.

Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.

Cancer patients who receive molecular testing results prior to beginning first-line treatment for metastatic nonsquamous non-small cell lung cancer appear to live longer.

Florida Cancer Specialists & Research Institute, LLC Director of Drug Development Manish Patel, MD is the co-author for two manuscripts published in the New England Journal of Medicine within two months.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome Board-certified hematologist and medical oncologist Tarek Eldawy, MD to the statewide practice.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Raphael Bosse, MD, PhD, has joined the statewide practice.

The use of best practice guidance and resources developed through the Positive Quality Intervention initiative of NCODA improves the quality of care provided to patients with blood cancers and disorders.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologists and medical oncologists Bahaa Amer, MD and Savan Shah, MD to the statewide practice.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice.

Florida Cancer Specialists & Research Institute is intentional in bringing world-class oncology and hematology care to patients.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologist and medical oncologist Tien Do, MD to the statewide practice. He is providing care to patients at the FCS Tallahassee Cancer Center, 2351 Phillips Road, Tallahassee, FL.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologist and medical oncologist Sireesha Datla, MD to the statewide practice.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Jayan Nair, MD has joined the the Sarasota Downtown clinical team.

Florida Cancer Specialists & Research Institute, LLC, physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with extensive-stage small cell lung cancer.

Lucio Gordan, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC, talked with Kevin Keegan, General Manager of Oncology Business with Illumina, about how FCS is bringing precision oncology through analysis of real-world data, innovative technology and research to cancer patients being treated in community settings.

The platinum drugs, carboplatin and cisplatin, known for effectively treating lung, head and neck, breast, ovarian, gastric, bladder and testicular cancers, have been in short order for the past few months.

Finding a comprehensive cancer care provider that is able to provide patients with swift and easy access to the highest-quality diagnosis and treatment planning is essential to reducing stress and ensuring patients achieve the best possible outcomes.

Florida Cancer Specialists & Research Institute has introduced a new technology that provides multiple benefits for cancer patients receiving radiation therapy at the FCS Ocala Cancer Center.

Florida Cancer Specialists & Research Institute President & Managing Physician Lucio N. Gordan, MD, will join an expert panel of precision medicine leaders in Chicago this weekend to discuss the impact of genomic profiling.

Results of year-long collaborative effort between Florida Cancer Specialists & Research Institute and CVS Health/Aetna documented in newly released case study.

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Florida Cancer Specialists & Research Institute, LLC continues to forge new partnerships with alternative payment models and payers

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.